Aging is associated with the decline of mitochondrial function, particularly in related metabolic diseases such as obesity, diabetes, and heart disease.
Researchers in Prof. Michael Lin's laboratory have developed a viral-based cancer therapy platform that could be used for targeting treatment to cancer cells with aberrant signaling in EGFR or HER2 pathways.
Despite widespread adoption of stationary wireless charging, dynamic wireless power transfer suffers from a sensitivity to relative movement of the device with respect to the power source.
Researchers at Stanford have developed prodrug derivatives of protein kinase C (PKC) modulators that have lower toxicity and are more effective than the parent compound. PKC modulators are being developed to treat a variety of diseases.
Researchers at Stanford have developed humanized therapeutic antibodies to treat cancers, particularly melanoma, inflammatory disorders such as sarcoidosis and skin and organ fibrosis.
RNA replication and amplification have broad applications across biomedicine, but current methods are limited by a reliance on inefficient, multi-step protocols.
Researchers in Prof. Stephen Quake's laboratory have developed a CRISPER-Cas-based targeted endonuclease system designed to treat latent viral infections by attacking the viral genome.
Dr. Francis Blankenberg has developed a method to prevent the spread of Listeria and other obligate intracellular pathogens, including mycobacterium marinum, chlamydia trachomatis and parasitic infections.